XtalPi is a quantum-physics, AI-powered Research and Development company based in Cambridge, MA, with branches in China. They are breaking barriers by being fairly early to hop into drug discovery intersecting with artificial intelligence. Essentially, they are looking to automate a decent amount of the drug discovery process, which allows for innovation like no other. Check out the video below to learn how XtalPi works to automate the process of drug development and bypasses many tasks that used to take hours of manpower.
XtalPi recently teamed up with the Experimental Drug Development Center (EDDC), which is Singapore’s national platform for drug discovery. Their collaboration is in regards to discovering treatment drugs for non-small cell lung cancer (NSCLC.)
Lung cancer is the leading cause of cancer-related mortality in the USA - the 5 year relative survival rate is as low as 22%. The need for a new treatment is urgent, especially for late-stage cancers.
That is where this collaboration with XtalPi and EDDC comes in - Xtalpi will leverage its expertise in artificial intelligence and deliver information about a potential target in NSCLC to EDDC. Xtalpi’s technology will be able to automate the screening of millions of molecules in drug design.That way, they can filter out the most promising molecules and pursue research on them. With this streamlining of targets, EDDC will analyze the drug itself, along with researching its chemical properties and various laboratory testing, which will ultimately result in additional knowledge about potential drugs.
This collaboration is great for the Singaporean company EDDC and the American-based Xtalpi with its various branches in China. Automating what used to take months, maybe even years, of work is truly remarkable. This is truly the future of drug design, especially with artificial intelligence. It will be interesting to see the drastic changes coming to the industry in the next few years with the highly-anticipated artificial intelligence boom.
References:
https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq